PDOX of Hematological Malignancy

  • LIDE has developed a novel method to establish Patient-Derived Orthotropic Xenografts of hematological malignancy. Tumor cell suspension generated freshly from bone marrow biopsy or peripheral blood will be inoculated into NCG mice intrafemorally. FACS analysis will be performed periodically using whole blood from the mice to determined engraftment of such PDOX, whereas spleen will be the tumor source for PDOX cryopreservation of mice passage for further in vivo efficacy study.

Flowchart of Hematological Malignancy PDOX establishment

 

  • LIDE has established over 20 hematological malignancy PDOXs including AML, ALL, multiple myeloma, and different kinds of lymphoma.

Model ID

Sex

Age

PDX pathology

PDX s.c.

PDOX i.f.

LD1-0041-362047

Male

51

ALL

Y

Y

LD1-0041-362073

Male

64

ALL

Y

Y

LD1-0041-362356

Male

53

ALL

Y

Y

LD1-0041-362478

Male

15

ALL

Y

Y

LD1-1041-362519

Female

38

ALL

N/A

Y

LD1-0041-362021

Male

32

ALL

N/A

Y

LD1-0040-361280

Female

38

AML

Y

Y

LD1-0040-361293

Female

61

AML

Y

Y

LD1-0040-362349

Male

23

AML

Y

Y

LD1-0040-362384

Male

59

AML

N/A

Y

LD1-0040-362030

Female

56

AML

N/A

Y

LD1-0040-361780

Male

49

AML

N/A

Y

LD1-0040-362224

Male

75

AML

N/A

Y

LD1-0040-362369

Male

57

AML

Y

Y

LD1-0040-362393

Female

57

AML

Y

Y

LD1-0040-362499

Male

68

AML

N/A

Y

LD1-0040-362575

Female

31

AML

Y

Y

LD1-0026-362219

Male

24

Burkitt's lymphoma

Y

N/A

LD2-0026-200614

Male

/

CLL transit to DLBCL

Y

N/A

LD1-0026-362314

Male

51

Mantle cell lymphoma

Y

N/A

LD1-0029-361915

Male

62

Multiple myeloma

Y

N/A

LD1-0029-361847

Male

54

Multiple myeloma

Y

N/A

LD1-0006-370728

Male

68

Multiple myeloma

Y

N/A